ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Psoriatic arthritis"

  • Abstract Number: 1850 • ACR Convergence 2022

    Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients with Active Psoriatic Arthritis Through 2 Years of DISCOVER-2

    Jeffrey Curtis1, Iain B McInnes2, Proton Rahman3, Dafna Gladman4, Feifei Yang5, Steve Peterson5, Alexa Kollmeier6, Natalie Shiff7, Chenglong Han8, May Shawi9, William Tillett10 and Philip J Mease11, 1Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 3Memorial University, St. John's, NL, Canada, 4Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 5Department of Immunology, Janssen Global Services, LLC, Horsham, PA, 6Janssen-Cilag, Research & Development, LLC, San Diego, CA, 7Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA, 8Immunology, Janssen Research & Development, LLC, Spring House, PA, 9Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 10Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 11Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

    Background/Purpose: Psoriatic arthritis (PsA), a chronic inflammatory disease characterized by peripheral arthritis, axial inflammation, dactylitis, enthesitis, and skin/nail psoriasis, is associated with reduced health-related quality…
  • Abstract Number: 2123 • ACR Convergence 2022

    Hierarchical Ranking of Biologic Disease-Modifying Antirheumatic Drugs and Targeted Systemic Therapies for Psoriatic Arthritis: A Network Meta-analysis

    Jesus Diaz1, Guillermo Quiceno2 and Adela Castro3, 1Hamilton Medical Center, Chattanooga, TN, 2UT Southwestern Medical Center, Dallas, TX, 3Hamilton Physician Group-Specialty Care, Dalton, GA

    Background/Purpose: There are an increasing number of biological and targeted DMARDs in PsA. However, challenges around treatment selection remain, given the few head-to-head studies directly…
  • Abstract Number: 2140 • ACR Convergence 2022

    Exposure-Adjusted Incidence Rate for Adverse Events of Special Interest in Patients with Psoriatic Arthritis Treated with Apremilast

    Philip J Mease1, Dafna Gladman2, Georg Schett3, Maria Paris4, Sue Cheng5, Sven Richter5, Lichen Teng5 and Arthur Kavanaugh6, 1Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 2Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 3Universitätsklinikum Erlangen, Erlangen, Germany, 4Amgen Inc., Westfield, NJ, 5Amgen, Inc., Thousand Oaks, CA, 6University of California San Diego, La Jolla, CA

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic systemic inflammatory musculoskeletal disease. The potential relationship between PsA therapies and specific safety events such as major adverse…
  • Abstract Number: 2206 • ACR Convergence 2022

    Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study

    Lihi Eder1, Fangya Ma2, Josefina Marin3, Minna Kohler4, Janeth Yinh5, Ari Polachek6, Marcos Rosemffet7, Ernesto Rodriguez8, Ilaria Tinnazzi9, Amir Haddad10, Philippe Carron11, Mariana Alves Ferreira Martins12, Catherine Bakewell13, Fahmeen J. Afgani14, Richard Cook2, Sibel Aydin15 and Gurjit S. Kaeley16, 1Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, 2University of Waterloo, Waterloo, ON, Canada, 3Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Massachusetts General Hospital, Harvard Medical School, Boston, MA, 5Massachusetts General Hospital, Boston, MA, 6Tel Aviv Medical Center, Tel Aviv, Israel, 7Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, 8Florida Medical Clinic, Tampa, FL, 9Ospedale Sacro Cuore-Don Calabria, Negrar, Italy, 10Carmel Medical Centre, Haifa, Israel, 11Ghent University Hospital, Ghent, Belgium, 12São José Do Rio Preto Medical School, São José do Rio Preto, Brazil, 13Intermountain Healthcare, Salt Lake City, UT, 14Women's College Hospital, Toronto, ON, Canada, 15University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada, 16UF COM-J, Ponte Vedra Beach, FL

    Background/Purpose: Variability in scoring of sonographic entheseal lesions may be influenced by patient characteristics and sonographer expertise. We aimed to assess inter-rater agreement in scoring…
  • Abstract Number: 0082 • ACR Convergence 2022

    Impact of the COVID-19 Pandemic on Healthcare Utilization Among Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus Patients

    Jean Park, W. Cliff Rutter, Will Cavers, Elisea Avalos-Reyes and Kjel Johnson, CVS Health, Lincoln, RI

    Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE) are considered at risk for serious COVID infections due to their…
  • Abstract Number: 0390 • ACR Convergence 2022

    Persistent Post-Covid Symptoms in Psoriatic Arthritis Patients

    Sonia Pastor Navarro1, Marta Ibáñez Martínez1, Olga Compán Fernández1, Belén Miguel Ibáñez1, Olga Martínez González1, Cristina Hidalgo Calleja1, Ana Isabel Turrión Nieves1, Susana Gómez Castro2 and Carlos Montilla Morales1, 1Hospital Universitario de Salamanca, Salamanca, Spain, 2Hospital Universitario Salamanca, Salamanca, Spain

    Background/Purpose: Symptomatic onset long after recovery from the acute phase of COVID-19 infection has been reported by the population. Currently, it is not known how…
  • Abstract Number: 0796 • ACR Convergence 2022

    SARS-CoV-2 Vaccine in Axial Spondyloarthritis and Psoriatic Arthritis: Does Sulfasalazine Counterbalance TNFI Impaired Immunogenicity?

    Carla Goncalves Schahin Saad1, Matheus SR Silva2, PERCIVAL SAMPAIO-BARROS1, Julio Moraes3, Claudia G Schainberg2, Celio Roberto goncalves1, Andrea Shimabuco1, Nadia Aikawa1, Emily Figueiredo Neves Yuki1, Sandra Gofinet Pasoto4, Leonard VK Kupa2, Renato K Aoyama2, Carlo Araujo1, Clovis A. Silva5, ana Medeiros6 and Eloisa Silva Dutra de Oliveira Bonfa4, 1Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Faculdade de Medicina da Universidade de São Paulo, São Paulo, 3Faculdade de Medicina da Universidade de Sao Paulo, Jundiai, Brazil, 4Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 5Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil, 6Faculdade de Medicina da Universidade de São Paulo, São Jose Dos Campos, Brazil

    Background/Purpose: Spondyloarthritis(SpA) patients are exposed to a variety of immunosuppressors capable of reduce humoral responses to vaccination. In context of the SARS-CoV-2 pandemic, assessment of…
  • Abstract Number: 1028 • ACR Convergence 2022

    How Does PsAID Implementation Affect Treatment Intensification and Patient Satisfaction in PsA?

    Conor Coyle1, Caroline Whately-Smith2, Melanie Brooke3, Uta Kiltz4, Ennio Lubrano5, Ruben Queiro6, David Trigos7, Jan Brandt-Juergens8, Salvatore D'Angelo9, Andrea Delle Sedie10, Emmanuelle Dernis11, Philip Helliwell12, Pauline Ho13, Axel Hueber14, BEATRIZ E. JOVEN15, Michaela Koehm16, Carlos Montilla17, Jon Packham18, JOSE PINTO TASENDE19, Felipe Julio Ramirez Garcia20, Adeline Ruyssen-Witrand21, Rossana Scrivo22, sarah twigg23, Martin Welcker24, Theo Wirth25, Laure Gossec26 and Laura Coates27, 1Oxford University Hospitals NHS Trust, Oxford, United Kingdom, 2Whately-Smith Ltd, Kings Langley, United Kingdom, 3Bath Institute for Rheumatic Disease, Bath, United Kingdom, 4Rheumazentrum Ruhrgebiet, Herne, Germany, 5Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ‘‘Vincenzo Tiberio’’, Università degli Studi del Molise, Campobasso, Italy, 6Faculty of Medicine, Rheumatology Service & the Principality of Asturias Institute for Health Research (ISPA), Universidad de Oviedo, Oveido, Spain, 7Patient partner, Oveido, Spain, 8Rheumatologische Schwerpunktpraxis, Berlin, Germany, 9Rheumatology Department of Lucania - San Carlo Hospital of Potenza, Potenza, Italy, 10University of Pisa, Pisa, Pisa, Italy, 11LE MANS general hospital, LE MANS, France, 12Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 13The Kellgren Centre for Rheumatology, Manchester, United Kingdom, 14Paracelsus University Nürnberg, Erlangen, Germany, 15Hospital Universitario 12 de Octubre, Madrid, Spain, 16Rheumatology Goethe-University Frankfurt, Frankfurt Am Main, Germany, 17Complejo asistencial Universitario de Salamanca, Salamanca, Spain, 18University of Nottingham, Stafford, United Kingdom, 19SERGAS, A Coruña, Spain, 20Hospital Clínic, Barcelona, Spain, 21CHU de Toulouse, Toulouse, France, 22Rheumatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy, Roma, Rome, Italy, 23Bradford Teaching hospitals NHS foundation trust, Bradford, United Kingdom, 24GBR, Planegg, Germany, 25Aix Marseille University, Marseille, France, 26Sorbonne Université, Paris, France, 27Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom

    Background/Purpose: Psoriatic arthritis (PsA) is a heterogenous, multi-dimensional disease. Little is known about factors underpinning treatment intensification in routine practice. Treatment pathways are not well…
  • Abstract Number: 1161 • ACR Convergence 2022

    IL-36-receptor Antagonist-Antibodies in Psoriasis and Psoriatic Arthritis

    Marie-Christin Hoffmann1, Natalie Fadle1, Evi Regitz1, Klaus-Dieter Preuss1, Marina Zaks2, Elisabeth Stöger3, Vincent Zimmer4, Philipp Klemm5, Gunter Assmann6, Bernhard Thurner7, Claudia Pföhler8, Joerg Thomas Bittenbring1, Christoph Kessel9 and Lorenz Thurner1, 1José Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany, 2Department of Nephrology and Internal Intensive Care, Charité University Medicine Berlin, Campus Virchow Clinic, Berlin, Germany, 3Evangelische Kliniken Essen-Mitte gGmbH, Evangelische Huyssens-Stiftung Essen-Huttrop, Essen, Germany, Essen, Germany, 4Department of Medicine, Knappschaftsklinikum Saar, Püttlingen, Germany, Department of Medicine II, Saarland University Medical School, Homburg/Saar, Germany, 5Campus Kerckhoff of Justus Liebig University Giessen, Bad Nauheim, Germany, 6Klinik für Rheumatologie und klinische Immunologie, Mühlenkreiskliniken, Johannes Wesling Klinikum Minden, Minden, Germany, Minden, Germany, 7Department of Pediatrics, Klinikum Kempten, Kempten, Germany, 8Department of Dermatology, Saarland University Medical School, Homburg/Saar, Germany, 9Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany, Münster, Germany

    Background/Purpose: Psoriasis arthritis is known as a subtype of seronegative spondylarthritis. However, autoantibodies against the receptor antagonist at tumor necrosis factor receptor 1 and 2…
  • Abstract Number: 1487 • ACR Convergence 2022

    Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23

    James Krueger1, Kilian Eyerich2, Dennis McGonagle3, Carrie Greving4, Kacey Sachen4, Deepa Hammaker4, Phuc Bao4, Eilyn Lacy4, M. Merle Elloso5, Yevgeniya Orlovsky5, Iain B McInnes6 and Anne Fourie7, 1The Rockefeller University, New York, NY, 2Technical University, Munich, Germany / Karolinska Institute, Stockholm, Sweden, 3University of Leeds, Leeds, UK, Leeds, United Kingdom, 4Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, 5Janssen Research and Development, LLC, Spring House, PA, 6Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 7Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, CA

    Background/Purpose: Clinically relevant differences between therapeutic antibodies against the same target may relate to their unique molecular attributes. Differences in therapeutic profiles across the domains…
  • Abstract Number: 1597 • ACR Convergence 2022

    Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial

    Frank Behrens1, Peter Taylor2, Philip J Mease3, Paul Peloso4, Dieter Wetzel5, Nicolai Brun5, Brian Wiens6, Jan Brandt-Juergens7, Edit Drescher8, Eva Dokoupilova9, Anna Rowińska-Osuch10, Nadia Abdel- Kader Martin11 and Kurt de Vlam12, 1Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, 2University of Oxford, Oxford, United Kingdom, 3Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 4ACELYRIN, Naples, FL, 5Affibody AB, Solna, Sweden, 6ACELYRIN, Inc., Los Angeles, CA, 7Rheumatologische Schwerpunktpraxis, Berlin, Germany, 8Veszprem Megyei Csolnoky Ferenc Korhaz, Budapest, Hungary, 9Medical Plus, s.r.o. & Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Brno, Prague, Czech Republic, 10ETG Network - Rheumatology, Warsaw, Poland, 11Hospital Infanta Luisa Quiron, Rheumatology, Sevilla, Spain, 12University Hospitals Leuven, Leuven, Belgium

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic, inflammatory disease with multiple clinical manifestations (arthritis, spondylitis, enthesitis, dactylitis, skin, nails). IL-17 inhibitors have shown efficacy across…
  • Abstract Number: 2108 • ACR Convergence 2022

    Changes in Serum Cytokines by Week 24 Correlate with Long-Term Efficacy of Guselkumab Through Two Years in Bio-Naïve Adults with PsA

    Stefan Siebert1, Georg Schett2, Siba P. Raychaudhuri3, Monica Guma4, Warner Chen5, Sheng Gao5, Soumya Chakravarty6, May Shawi7 and Proton Rahman8, 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, 2Universitätsklinikum Erlangen, Erlangen, Germany, 3Rheumatology, Allergy, and Clinical Immunology, University of California Davis, School of Medicine, Sacramento, CA, 4Division of Rheumatology, Allergy, and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, 5Janssen Research and Development, LLC, Spring House, PA, 6Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, 7Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 8Memorial University, St. John's, NL, Canada

    Background/Purpose: The IL-23p19 inhibitor guselkumab has shown robust efficacy vs placebo (PBO) in the phase 3 DISCOVER-1 and DISCOVER-2 studies of adults with active PsA,1,2…
  • Abstract Number: 2124 • ACR Convergence 2022

    Immunological Differences Between PsA Patients Who Are Tumor Necrosis Factor Inhibitor-Naïve and Who Have Inadequate Response to Tumor Necrosis Factor Inhibitors

    Stefan Siebert1, Laura Coates2, Georg Schett3, Siba P. Raychaudhuri4, Warner Chen5, Sheng Gao5, Soumya Chakravarty6, May Shawi7, Frederic Lavie8, Elke Theander9, Marlies Neuhold10, Alexa Kollmeier11, Xie L Xu12, Proton Rahman13, Philip J Mease14 and Atul Deodhar15, 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, 3Universitätsklinikum Erlangen, Erlangen, Germany, 4Rheumatology, Allergy, and Clinical Immunology, University of California Davis, School of Medicine, Sacramento, CA, 5Janssen Research and Development, LLC, Spring House, PA, 6Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, 7Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 8The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, Paris, France, 9Janssen Cilag, Lund, Sweden, 10Janssen, Zug, Switzerland, 11Janssen-Cilag, Research & Development, LLC, San Diego, CA, 12Janssen Research & Development, LLC, San Diego, CA, USA, San Marcos, CA, 13Memorial University, St. John's, NL, Canada, 14Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 15Oregon Health & Science University, Portland, OR, USA, Portland, OR

    Background/Purpose: A better understanding of the immunological differences between psoriatic arthritis (PsA) patients (pts) who are tumor necrosis factor inhibitor (TNFi)-naïve and who have inadequate…
  • Abstract Number: 2141 • ACR Convergence 2022

    How Well Does Ultrasound-assessed Synovitis in Reduced Joint Sets Predict the Response to Secukinumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Conventional DMARDs? – Exploratory Results from a Phase 3b Study

    Maria-Antonietta D'Agostino1, Philip G Conaghan2, Corine Gaillez3, Esperanza Naredo4, Peter mandl5, Philippe Carron6, Ladislav Šenolt7, Javier Eduardo Rosa8, Alejandra Lopez Rdz9, Punit Goyanka10, Braja Gopal Sahoo10, Weibin Bao11, Georg Schett12 and Maarten Boers13, 1Catholic University of Sacred Heart, Roma, Italy, 2University of Leeds, Leeds, United Kingdom, 3Novartis Pharma AG, Basel, Switzerland, 4Hospital General Universitario Gregorio Marañón and Complutense University, Madrid, Spain, 5Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Wien, Austria, 6Ghent University Hospital, Ghent, Belgium, 7Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 8Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 9Dermatológico Country, PSOAPS Psoriasis Clinical and Research Centre, Guadalajara, Mexico, 10Novartis Healthcare Pvt Ltd, Hyderabad, India, 11Novartis Pharmaceuticals Corporation, East Hanover, NJ, 12Universitätsklinikum Erlangen, Erlangen, Germany, 13Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands

    Background/Purpose: Power Doppler ultrasound (PDUS) allows the visualization of morphological and inflammatory changes of the synovium. The ULTIMATE study (NCT02662985) was the first large, randomized,…
  • Abstract Number: 2256 • ACR Convergence 2022

    Increased Brain Functional Connectivity to the Insula Is Associated with Nociplastic Pain in Psoriatic Arthritis

    Flavia Sunzini1, Kristian Stefanov1, Salim Al-Wasity1, Steven E Harte2, Richard E Harris2, Daniel J Clauw2, Stefan Siebert3, Carl Goodyear1, Gordon Waiter4 and Neil Basu1, 1University of Glasgow, Glasgow, Scotland, United Kingdom, 2University of Michigan, Ann Arbor, MI, 3Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, 4University of Aberdeen, Aberdeen, Scotland, United Kingdom

    Background/Purpose: Pain is a hallmark feature of psoriatic arthritis (PsA); however, its apparent multi-factorial nature makes it difficult for rheumatologists to assess and manage. Clinically,…
  • « Previous Page
  • 1
  • …
  • 37
  • 38
  • 39
  • 40
  • 41
  • …
  • 93
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology